Exagen (NASDAQ:XGN) Price Target Cut to $10.00 by Analysts at Craig Hallum

Exagen (NASDAQ:XGN) had its target price decreased by stock analysts at Craig Hallum from $12.00 to $10.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Craig Hallum’s price target points to a potential upside of 212.11% from the stock’s previous close.

Several other brokerages have also recently issued reports on XGN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Exagen in a research note on Wednesday, January 21st. William Blair reaffirmed an “outperform” rating on shares of Exagen in a report on Tuesday. KeyCorp cut their target price on Exagen from $15.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday. TD Cowen reduced their target price on Exagen from $13.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, February 24th. Finally, BTIG Research decreased their price target on Exagen from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Tuesday. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Exagen currently has an average rating of “Moderate Buy” and an average price target of $10.29.

Exagen Stock Performance

NASDAQ:XGN traded down $0.05 during mid-day trading on Wednesday, reaching $3.20. 61,152 shares of the company’s stock were exchanged, compared to its average volume of 518,347. Exagen has a one year low of $2.91 and a one year high of $12.23. The company has a debt-to-equity ratio of 1.35, a quick ratio of 4.08 and a current ratio of 4.08. The business’s fifty day simple moving average is $4.24 and its two-hundred day simple moving average is $7.53. The firm has a market capitalization of $72.60 million, a PE ratio of -3.48 and a beta of 1.88.

Exagen (NASDAQ:XGN) last posted its quarterly earnings data on Tuesday, March 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.20). Exagen had a negative net margin of 29.94% and a negative return on equity of 113.48%. The firm had revenue of $16.63 million during the quarter, compared to the consensus estimate of $16.46 million. Analysts anticipate that Exagen will post -0.88 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Exagen news, CEO John Aballi sold 15,698 shares of the business’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $3.62, for a total transaction of $56,826.76. Following the completion of the transaction, the chief executive officer directly owned 687,299 shares in the company, valued at $2,488,022.38. The trade was a 2.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 12.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Exagen

Several hedge funds and other institutional investors have recently modified their holdings of the business. Acadian Asset Management LLC bought a new stake in shares of Exagen during the 1st quarter worth $25,000. Truvestments Capital LLC grew its position in Exagen by 109.5% in the fourth quarter. Truvestments Capital LLC now owns 6,169 shares of the company’s stock valued at $38,000 after acquiring an additional 3,225 shares during the last quarter. Persistent Asset Partners Ltd acquired a new position in Exagen during the fourth quarter worth about $80,000. Schonfeld Strategic Advisors LLC acquired a new position in Exagen during the fourth quarter worth about $82,000. Finally, Jain Global LLC bought a new position in shares of Exagen in the fourth quarter worth about $82,000. Institutional investors own 75.25% of the company’s stock.

More Exagen News

Here are the key news stories impacting Exagen this week:

• Positive Sentiment: Record revenue and test‑volume growth — Exagen reported strong Q4 and full‑year 2025 results, with record total revenue, higher AVISE CTD average selling price and >11% year‑over‑year test volume growth, supporting commercial momentum. Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results
• Positive Sentiment: Analyst support remains — BTIG lowered its price target from $10 to $9 but maintained a “buy” rating, implying significant upside from current levels and signaling continued analyst conviction in the growth story. Exagen (XGN) PT Lowered to $9 at BTIG
• Positive Sentiment: Commercial investment ramp — Management highlighted expansion of the sales force and an accelerated innovation cadence as drivers for 2026 growth, which could support higher ASPs and incremental test volume over time. Exagen outlines $70M–$73M 2026 revenue target while expanding sales force and innovation cadence
• Neutral Sentiment: Q4 earnings in line — EPS loss of ($0.20) matched consensus while revenue of $16.63M modestly beat estimates, leaving profitability progress largely unchanged in the near term. Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates
• Neutral Sentiment: Earnings materials available — The company posted its earnings release, slide deck and the full call transcript for investors who want detail on commercial cadence and margin targets. Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript
• Negative Sentiment: FY‑2026 revenue guide misses consensus — Management guided revenue of $70.0M–$73.0M for 2026 versus a roughly $74M consensus, a modest shortfall that likely prompted some of the intra‑day selling pressure. Press Release / Slide Deck
• Negative Sentiment: Short interest rising — Short interest increased ~21% in February to roughly 1.07M shares (~5.4% of float) with a ~4‑day days‑to‑cover, indicating growing bearish positioning that can amplify downside on weak news or liquidity events.

Exagen Company Profile

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.